Author: Editor

Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses Sensitivity Of cfDNA Method. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses Immune Signatures & Positioning Biopsy Needle. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses The ADAPTeR Study. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses Elaborating On Cell-Free DNA (cfDNA). At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Dr. Ash Tewari discusses the concept of race vs. genetics in Health Disparity research and treatment

Philadelphia, PA (April 9, 2019) –  Oncoceutics announced today the publication of an article entitled “First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M–mutant pediatric diffuse intrinsic pontine glioma: a case report” in the Journal of Neurosurgery (authored by Matthew D. Hall, M.D., MBA). The article summarizes the medical history of a 10-year-old girl with a diffuse intrinsic pontine glioma (DIPG) brain tumor. Following radiation therapy and treatment with ONC201 on a compassionate use basis, she developed near complete resolution of her presenting neurological symptoms for almost one year, enabling her return to school and participation in many normal activities.DIPG is a…

Earn CME credit: https://www.naccme.com/program/2018-i7956-1 PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have expanded in recent months. This roundtable discussion between Dr. Robert L. Coleman and pharmacy experts in PARP treatment for ovarian cancer is specifically designed for health-system pharmacists, including specialty pharmacists, clinical pharmacists, oncology pharmacists, and other pharmacists involved in the management of patients with ovarian cancer. © 2018 Imedex, an HMP Company

Dr. Ben Levy discusses two trials that are trying to determine if Immunotherapy can help lung cancer patients with earlier stage disease. Click here for information about the PACIFIC trial. The lung cancer vaccine trial will begin in early 2016.

Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.

Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon, medical oncologist at UCLA, summarizes key data and explains their current role in treatment.

Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.

Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used to select patients to receive or not receive immune checkpoint inhibitor therapy in lung cancer.

Earn CME Credit: https://www.naccme.com/program/7327 Knowledge is evolving regarding numerous clinical aspects of immune thrombocytopenic purpura (ITP), and there remains significant variability in clinical practice patterns for its management. This activity features Drs. David P. Steensma and Ilene C. Weitz sharing their insights about data recently released in publication form pertaining to pharmacotherapy for ITP, with a focus on the use of thrombopoietin (TPO) receptor agonists. © 2019 Imedex, an HMP Company

Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a driver mutation (EGFR, ALK, etc.) reliably predict minimal benefit from immunotherapy agents.

Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies with one another.

Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.

Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.

Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.

Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed. Additional investors participating in the round are Perceptive Advisors, Pivotal bioVenture Partners, and Rock Springs Capital, along with the existing group of leading international investors, that include HealthCap, Adams Street Partners, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), TPG Biotech, Seroba Life Sciences, Genesys Capital, and FACIT. In conjunction with the new financing, Deepak Khuntia, Senior Vice President (SVP) and Chief Medical Officer (CMO) at Varian, Chau Q. Khuong, Partner at OrbiMed, and Heather Preston, Managing Director at Pivotal bioVenture Partners, will…

SOUTH SAN FRANCISCO, Calif., April 2, 2019 /PRNewswire/ – ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on the discovery and development of novel therapies against treatment-resistant cancers, today presented new preclinical data on its lead program ORIC-101, a selective and potent glucocorticoid receptor (GR) antagonist, at the American Association of Cancer Research (AACR) Annual Meeting in Atlanta, GA. The data were presented in a poster “ORIC-101 Reverses a GR-Driven EMT-like Phenotype and Sensitizes TNBC Cells to Chemotherapy (Abstract #3822)” during the Experimental and Molecular Therapeutics poster session. The Company’s research findings provide insight into the molecular basis of GR-mediated…

April 02, 2019 08:00 ET | Source: Cybrexa Therapeutics     Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in HRD negative tumors   Poster presentation today during AACR Annual Meeting 2019 NEW HAVEN, Conn., April 02, 2019 (GLOBE NEWSWIRE) — Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalexâ„¢ tumor targeting platform, today announced that the FDA- and EMA-approved poly ADP-ribose polymerase (PARP) inhibitor rucaparib (marketed as Rubraca®) is conjugated in lead candidate CBX-11 (alphalexâ„¢-rucaparib). The first set of preclinical data supporting CBX-11 demonstrate that Cybrexa’s proprietary alphalexâ„¢ platform can enable full dose administration…

Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of “liquid biopsies”, serum-based testing for molecular marker testing in lung cancer.

Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced NSCLC and highlights details of two trials testing this question.

Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

Dr. Seema Nagpal insists on one thing from her lung cancer patients: Proof that they are enjoying their lives. November is Lung Cancer Awareness Month. What are you grateful for?

Daniel Goldstein MD Tel Aviv University discusses Moving from Observational Pharmacoeconomics to Interventional Pharmacoeconomics at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Cristina Suárez MD PhD Hospital Universitari Vall d´Hebron-Vall d´Hebron Institute of Oncology discusses SPAIN: SOGUG MODEL at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Tim OBrien Vice President of BAUS discusses Centralization of Nephrectomy in the UK The good the bad and the ugly at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Toni K. Choueiri, MD Director, The Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute discusses The Combination of Avelumab + Axitinib (Ave/Axi) in Advanced RCC: a legitimate 1st line contender at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Ronan FlippotMD MSc discusses Brain Metastases in Renal Cell CarcinomaAre immune checkpoint inhibitors up to the task? discusses Brain Metastases in Renal Cell CarcinomaAre immune checkpoint inhibitors up to the task? at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Raquel Perez-Lopez Vall dHebron Institute of Oncology (VHIO)Principal Investigator-Radiomics Group discusses Recist vs iRecist: Clinically Significant? at the Kidney Cancer Association International Symposium 2019 at Dubrovnik, Croatia         recist vs irecist, kidney cancer association international symposium 2019, clinically significant

Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of the American Association for Cancer Research Annual Meeting Cambridge, Mass. (March 29, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneeringtargeted protein degradation to create breakthrough medicines for patients, will present new preclinical data for its first-in-class oral IRAK4 protein degrader, KYM-001, in MYD88-mutant lymphoma. Data will be presented in a late-breaking research session at the American Association for Cancer ResearchAnnual Meeting on April 3 from 8 a.m. – 12 p.m. (Poster #18, Session: Experimental and Molecular Therapeutics 2). The…

Frede Donskov, M.D., DMSc Professor of Oncology Chairman, Kidney Cancer Expert Committee, Danish Medicines Council Aarhus University Hospital Denmark discusses the Nordic Registry Approach at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Brian i. Rini, MD Cleveland Clinic discusses Axi/Pembro is the Standard of Care in mRCC at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Samra Turajlic The Royal Marsden NHS Foundation Trust, London, UK discusses the second part of A phase II study of Anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell cancer (ADAPTeR) at the Kidney Cancer International Symposium 2019 in Dubrovnik, Croatia

Dr Pablo Maroto Hospital Sant Pau Barcelona discusses New Network Around Oncologists at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Jean-Marie Michot, MD Drug Development Department Gustave Roussy, France jean-marie.michot@gustaveroussy.fr discusses IO toxicities in Kidney Cancer at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology discusses  Update in IO Neoadjuvant (Preoperative) Trials at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Cristina Suárez MD PhD Hospital Universitari Vall d´Hebron-Vall d´Hebron Institute of Oncology discusses NEW TARGETS IN RCC:NKTR at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Brian Shuch, MD Associate Professor of Urology Director, UCLA Kidney Cancer Program Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research discusses Targeting RCC Metabolism: Glutaminase Inhibition at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Monika Wolkers, PhD m.wolkers@sanquin.nl discusses TIL products from Renal Cell Carcinomas are tumor-specific but poor cytokine producers at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Bernadett Szabados of Barts Cancer Institute discusses NEW TARGETS IN RCC at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Dr. Ross Camidge discusses a clinical trial studying patients with advanced stage lung cancer to identify those who may respond to a drug called ponatinib. Both small cell and non small cell lung cancer patients may be eligible.

Dr. Jack West reviews the concept of epigenetics, epigenetic priming, and whether oral azacytidine can improve outcomes in patients who receive immunotherapy for advanced lung cancer.

On this Thanksgiving Day, we salute lung cancer patient Jason Karg and his wife Kristyl for reminding us of the important things in life.

Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.

Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an “umbrella protocol” in which all patients undergo molecular testing and have treatment assigned by the results.

Gratitude is one of the most medicinal emotions we can feel. (Sara Avant Stover) Thank you for joining GRACE in our #LCAM15 activities.

As we learn more about immunotherapy for lung cancer, combinations with multiple immunotherapy agents are being explored. Medical oncologist Dr. Eddie Garon considers whether combinations are likely to emerge as the leading immunotherapy approach.